Please login to the form below

Not currently logged in
Email:
Password:

Swedish Orphan Biovitrum

This page shows the latest Swedish Orphan Biovitrum news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP also gave positive opinions to: a new maintenance indication for AstraZeneca and Merck &Co’s PARP inhibitor Lynparza (olaparib) in ovarian cancer; the use of Swedish orphan Biovitrum’s

Latest news

More from news
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions. “ ... The UK, in common with many developed markets, has large numbers of products that, while they do have a licence and are currently available, are

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. † Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum. Development, supply and commercialisation.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics